Treating and preventing liver cancer

Oct 4, 2021 | Jennifer O'Hara | @jenohara | Comments (4)

While still relatively rare, the rate of primary liver cancer has been increasing in recent decades, disproportionately affecting minority populations.

"Research has shown that Blacks and Hispanics are less likely to be diagnosed with liver cancer at an earlier stage, compared to whites," says Dr. Sumera Ilyas, a Mayo Clinic gastroenterologist. "And that, in turn, means the odds of being eligible for potentially curative treatments are lower for these patients."

These disparities are due to many potential reasons.

"These differences in diagnosis may be due to differences in access to primary or subspecialty health care. They may also be due to differences in surveillance," explains Dr. Ilyas.

The National Cancer Institute estimates that more than 42,000 new cases of liver cancer will be diagnosed in 2021, representing 2.2% of all new cancer cases in the U.S.

The most common type of primary liver cancer is hepatocellular carcinoma. Other types of liver cancer, such as intrahepatic cholangiocarcinoma and hepatoblastoma, are much less common.

"The vast majority of liver cancers — over 90% — occur in patients who have a chronic liver disease," says Dr. Ilyas. "Cirrhosis, or advanced scarring of the liver, is the strongest risk factor for hepatocellular carcinoma."

Chronic infection with the hepatitis B or hepatitis C viruses also increases your risk of liver cancer.

A wide range of treatment options for primary liver cancer are available. Which treatment is used depends on the stage of the disease.

On the Mayo Clinic Q&A podcast, Dr. Ilyas discusses liver cancer diagnoses and treatment options, and the importance of prevention.

To practice safe social distancing during the COVID-19 pandemic, this interview was conducted using video conferencing. The sound and video quality are representative of the technology used. For the safety of its patients, staff and visitors, Mayo Clinic has strict masking policies in place. Anyone shown without a mask was recorded prior to COVID-19 or recorded in an area not designated for patient care, where social distancing and other safety protocols were followed.

Read the full transcript.

For more information and all your COVID-19 coverage, go to the Mayo Clinic News Network and mayoclinic.org.

Connect with others talking about liver cancer, and supporting one another in the Cancer support group.

Interested in more newsfeed posts like this? Go to the Podcasts blog.

Thank you so much for this podcast on liver cancer. Since it is one of the less common cancers, there is less information they we generally hear about it. My brother and grandfather both died of primary liver cancer at relatively young ages, so I am profoundly interested to learn of new advances in detecting, treating, and hopefully someday, curing liver cancer.

REPLY

Thank you. I was however, surprised there was no mention of hepatitis C.

REPLY

Thank you for the information I have PBC and trying to learn all I can, never drank or drugs and did have hepatitis shots at workplace 30 years ago.

REPLY
@gema98

Thank you for the information I have PBC and trying to learn all I can, never drank or drugs and did have hepatitis shots at workplace 30 years ago.

Jump to this post

Gema, you might like to join others in this discussion about PBC.
- Primary Biliary Cholangitis and Autoimmune Hepatitis https://connect.mayoclinic.org/discussion/primay-biliary-cholagitis-and-autoimmune-hepattitis/

REPLY
Please sign in or register to post a reply.